We are excited to announce that Biomea Fusion will host a conference call and webcast to share the topline results from our Phase II COVALENT-111 study in patients with Type 2 Diabetes (T2D). 🗓 Date: Tuesday, December 17, 2024 ⏰ Time: 8:00 AM EST 🔗 Webcast Access: https://lnkd.in/ebdbdmA5 The COVALENT-111 study evaluates icovamenib, our novel covalent small molecule, as a potential new treatment option for patients with Type 2 Diabetes. At Biomea, we are dedicated to improving the lives of patients through the discovery and development of next-generation covalent therapies. Don’t miss this important milestone as we advance our mission to deliver breakthrough medicines. Replay: If you are unable to attend live, the webcast will be available as an archive. #BiomeaFusion #Type2Diabetes #COVALENT111 #ClinicalTrials #Biotech #Innovation
